Log in

Relevant bibliographies by topics / 342.9629 (043.2) / Journal articles

To see the other types of publications on this topic, follow the link: 342.9629 (043.2).

Journal articles on the topic '342.9629 (043.2)'

Author: Grafiati

Published: 30 May 2022

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic '342.9629 (043.2).'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Borad, Mitesh J., Shantan G. Reddy, Nathan Bahary, et al. "Randomized Phase II Trial of Gemcitabine Plus TH-302 Versus Gemcitabine in Patients With Advanced Pancreatic Cancer." Journal of Clinical Oncology 33, no. 13 (2015): 1475–81. http://dx.doi.org/10.1200/jco.2014.55.7504.

Full text

Abstract:

Purpose TH-302 is an investigational hypoxia-activated prodrug that releases the DNA alkylator bromo-isophosphoramide mustard in hypoxic settings. This phase II study (NCT01144455) evaluated gemcitabine plus TH-302 in patients with previously untreated, locally advanced or metastatic pancreatic cancer. Patients and Methods Patients were randomly assigned 1:1:1 to gemcitabine (1,000 mg/m2), gemcitabine plus TH-302 240 mg/m2 (G+T240), or gemcitabine plus TH-302 340 mg/m2 (G+T340). Randomized crossover after progression on gemcitabine was allowed. The primary end point was progression-free surviv

APA, Harvard, Vancouver, ISO, and other styles

2

Franco, Sandra, Lourdes Mateu, Raquel Pluvinet, et al. "Altered Plasma microRNA Signature in Hospitalized COVID-19 Patients Requiring Oxygen Support." Microorganisms 12, no. 3 (2024): 440. http://dx.doi.org/10.3390/microorganisms12030440.

Full text

Abstract:

To discover potential micro(mi)RNA biomarkers of SARS-CoV-2 infection and disease progression, large-scale deep-sequencing analysis of small RNA expression was performed on plasma samples from 40 patients hospitalized for SARS-CoV-2 infection (median 13.50 [IQR 9–24] days since symptoms initiation) and 21 healthy noninfected individuals. A total of 1218 different miRNAs were identified. When compared with healthy noninfected donors, SARS-CoV-2-infected patients showed significantly (fold change [FC] > 1.2 and adjusted p [padj] < 0.05) altered expression of 190 miRNAs. The top-10 differen

APA, Harvard, Vancouver, ISO, and other styles

3

Marincowitz, Carl, Omar Bouamra, Tim Coates, et al. "1427 The effect of the COVID-19 pandemic on major trauma presentations and patient outcomes in English hospitals." Emergency Medicine Journal 39, no. 12 (2022): A960.2—A964. http://dx.doi.org/10.1136/emermed-2022-rcem2.2.

Full text

Abstract:

Aims, Objectives and BackgroundThere is evidence that COVID-19 ‘lockdowns’ may have contributed to increased non-accidental injury, domestic violence and self-harm related to deteriorating mental health. Internationally, there is also evidence that the diversion of health care resources may led to worse outcomes for patients presenting with major trauma. There has been no previous national evaluation of ‘lockdown’ measures impact on the characteristics, treatment pathways and outcomes of trauma patients in EnglandWe aimed to assess the impact of successive lockdowns on the volume, demographics

APA, Harvard, Vancouver, ISO, and other styles

4

Fujii, Hisaki, Kevin She, Soudabeh Aslanian, et al. "Inflammatory Markers and Autoantibodies That Correlate with Early and Late Onset of New Onset Pediatric Chronic Graft-Versus-Host Disease (GVHD)." Blood 108, no. 11 (2006): 3232. http://dx.doi.org/10.1182/blood.v108.11.3232.3232.

Full text

Abstract:

Abstract Chronic graft-vs-host disease (cGVHD) has previously been characterized by elevation of a number of inflammatory markers and autoantibodies. We hypothesized that evaluation of such markers would contribute to a biological classification of new onset cGVHD in children and possibly aid in early diagnosis. The COG study ASCT0031 is a phase III cGVHD therapeutic trial that included the biological evaluation of 52 newly diagnosed cGVHD pts and 34 time-matched post BMT control patients (2 – 18 yrs) with no clinical evidence of cGVHD. Chronic GVHD was divided into an early onset between 3 to

APA, Harvard, Vancouver, ISO, and other styles

5

He, Xin, Kyriakie Sarafoglou, Patricia Y. Fechner, et al. "Changes in Adrenal and Gonadal Androgens After 14-Day Treatment With CRF1 Receptor Antagonist, Crinecerfont (NBI-74788), in Men With Classic 21-Hydroxylase Deficiency." Journal of the Endocrine Society 5, Supplement_1 (2021): A78. http://dx.doi.org/10.1210/jendso/bvab048.157.

Full text

Abstract:

Abstract Background: Congenital adrenal hyperplasia due to classic 21-hydroxylase deficiency (21OHD) causes cortisol insufficiency and androgen excess. A phase 2 trial of crinecerfont, a CRF1 receptor antagonist, in 18 adults with 21OHD showed prominent decreases in ACTH, 17-hydroxyprogesterone, and androstenedione (A4), and in women, testosterone (T), after 14 days of treatment. In men with 21OHD, T derives from both adrenals and testes; in poor disease control, A4/T ratio is elevated due to disproportionately increased adrenal A4 production and decreased testicular T production. We sought to

APA, Harvard, Vancouver, ISO, and other styles

6

Suttorp, Meinolf, Ralf Knoefler, Hélène Deutsch, et al. "High Platelet Counts, Thrombosis, Bleeding Signs, and Acquired Von Willebrand Syndrome at Diagnosis of Pediatric Chronic Myeloid Leukemia." Blood 134, Supplement_1 (2019): 4152. http://dx.doi.org/10.1182/blood-2019-123343.

Full text

Abstract:

Background: At diagnosis of chronic myeloid leukemia (CML) patients (pats) may present with elevated platelets (PLT) counts. Generally, high PLT counts may result in thrombosis and/or bleeding complications, the latter being due to binding of von Willebrand factor (VWF) multimers to platelets. Pediatric CML is very rare (Hijiya N, Suttorp M 2019; Blood 33:2374-2384) and no systematic investigation on clinical complications of elevated PLT counts has so far been reported. Methods: Data on PLT counts and associated thrombo-hemorrhagic complications were retrospectively analyzed in newly diagnose

APA, Harvard, Vancouver, ISO, and other styles

7

Siddiqui, S. H., N. Kumari, and N. Krishnani. "Histopathological Spectrum in Pancreaticoduodenectomy Specimens: Fifteen Year Study from a Tertiary Care Centre in North India." American Journal of Clinical Pathology 154, Supplement_1 (2020): S60. http://dx.doi.org/10.1093/ajcp/aqaa161.129.

Full text

Abstract:

Abstract Introduction/Objective The periampullary region is histologically complex owing to the confluence of three different kinds of epithelia (duodenal, pancreatic, biliary) harbouring four types of cancers. Although anatomical proximity warrants a common surgical approach, overall survival depends largely on the type of surgical indication. Malignant epithelial tumors are the predominant indications, accompanied by a myriad of benign tumors and tumor-like lesions. We reviewed our archival pancreaticoduodenectomies to analyze the spectrum of these lesions. Methods All pancreaticoduodenectom

APA, Harvard, Vancouver, ISO, and other styles

8

Dombret, Hervé, Alexandra Coelho, Laurène Fenwarth, et al. "Treatments and Outcomes of Adult Patients with AML in the Real-Life - First Report of the French Observational ALFA-PPP Study." Blood 144, Supplement 1 (2024): 2424. https://doi.org/10.1182/blood-2024-207226.

Full text

Abstract:

Introduction. AML treatment options have been recently enriched. New agents like gemtuzumab ozogamicin (GO), FLT3 or IDH inhibitors, or CPX-351 have been approved for some patient subsets. Less-intensive options, like the AZA-VEN combination, are used in older/unfit patients. However, while treatments and indications are standardized, their choice is not, depending on often-subjective factors. This makes observational studies so important to describe the real-life management and outcomes of AML patients. Methods. In 2022, the ALFA group initiated a 2-cohort (newly diagnosed, relapsed/refractor

APA, Harvard, Vancouver, ISO, and other styles

9

Ishibashi, Toshihiro. "Can Transcranial Ultrasonication Increase Recanalization Flow Ratio with Tissue Plasminogen Activator?" Stroke 32, suppl_1 (2001): 360. http://dx.doi.org/10.1161/str.32.suppl_1.360-d.

Full text

Abstract:

P119 Purpose: The enhancement by a newly developed method of transcranial ultrasonication (TU) of thrombolysis with tissue plasminogen activator (TPA) was investigated in acute ischemic stroke (AIS) with an in vivo rabbit femoral artery occlusion model. Method: The femoral arteries of 36 rabbits were exposed, and stenosis was produced with 5–0 silk suture to reduce the flow to 77.3±6.9%. Poststenotic flow was measured with a flow meter at proximal segments of the femoral artery. Thrombosis was achieved by injecting thrombin through the cannulated branching artery into a 1-cm segment proximal t

APA, Harvard, Vancouver, ISO, and other styles

10

Magrey, M., M. G. H. Van de Sande, M. Breban, et al. "POS1107 BIMEKIZUMAB ACHIEVED SUSTAINED IMPROVEMENTS IN EFFICACY OUTCOMES IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS, REGARDLESS OF PRIOR TNF INHIBITOR TREATMENT: WEEK 52 POOLED RESULTS FROM TWO PHASE 3 STUDIES." Annals of the Rheumatic Diseases 82, Suppl 1 (2023): 876–77. http://dx.doi.org/10.1136/annrheumdis-2023-eular.836.

Full text

Abstract:

BackgroundIn patients (pts) with axial spondyloarthritis (axSpA), tumour necrosis factor inhibitors (TNFi) are the usual first line biologic treatment, yet many pts may experience loss of response over time, and some are intolerant to TNFis.[1]Typically, response to second line biologics is limited in TNFi-inadequate responders (IR).Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits IL-17F in addition to IL-17A. In the phase 3 BE MOBILE 1 and 2 studies, BKZ treatment resulted in rapid and sustained improvements in efficacy outcomes through 52 weeks (wks) in pts with acti

APA, Harvard, Vancouver, ISO, and other styles

11

Jayaprakash, Priyamvada, Meghan Rice, Krithikaa Rajkumar Bhanu, et al. "622 Disrupted oxygen supply and tumor hyper- oxygen consumption contribute independently to prostate cancer immune privilege." Journal for ImmunoTherapy of Cancer 9, Suppl 2 (2021): A652. http://dx.doi.org/10.1136/jitc-2021-sitc2021.622.

Full text

Abstract:

BackgroundDespite the success of immunotherapy in immune-infiltrated ”hot” tumors like melanoma, ”cold” tumors like prostate cancer remain unresponsive [1,2,3]. We find that these tumors harbor regions of hypoxia that act as islands of immune privilege that exclude T cells, while retaining immunosuppressive myeloid cells. Targeting hypoxia using the hypoxia-activated prodrug, TH-302 (Evofosfamide) reduced hypoxic regions and co-operated with immune checkpoint blockade (anti-CTLA-4+anti PD-1) to drive tumor regression in transplantable and spontaneous murine prostate tumors [4]. In a Phase I cl

APA, Harvard, Vancouver, ISO, and other styles

12

Castrejon, I., J. Molina Collada, C. Perez-Garcia, et al. "POS1439 CANCER IN PATIENTS WITH RHEUMATIC DISEASES EXPOSED TO DIFFERENT BIOLOGIC AND TARGETED SYNTHETIC DMARDS IN REAL-WORLD CLINICAL PRACTICE: DATA FROM A MULTICENTER REGISTER." Annals of the Rheumatic Diseases 81, Suppl 1 (2022): 1063. http://dx.doi.org/10.1136/annrheumdis-2022-eular.3834.

Full text

Abstract:

BackgroundExtensive evidence has confirmed no increased risk of cancer associated to either conventional synthetic DMARDs or anti-TNF in patients with rheumatic diseases. The risk of cancer in biologic (bDMARDs) different to anti-TNF and targeted synthetic (tsDMARDs) is considerably less investigated. As new therapies are emerging, more data in real-world registries are needed to confirm safety in other treatment groups.ObjectivesTo compare the risk of cancer of tsDMARDs and other bDMARDs versus anti-TNF in patients with rheumatic diseases.MethodsData of patients enrolled in BIOBADASER 3.0 up

APA, Harvard, Vancouver, ISO, and other styles

13

Fong, Yeap Cai, and Alexis Lordudass. "WHEN THYROID STIMULATING HORMONE AND FREE THYROXINE MISMATCH." Journal of the ASEAN Federation of Endocrine Societies 40, S1 (2025): 159–60. https://doi.org/10.15605/jafes.040.s1.269.

Full text

Abstract:

INTRODUCTIONThyroid hormone resistance (THR) is characterized by lack of end-organ responsiveness to thyroid hormone with high serum free thyroxine (FT4) with inappropriately high thyroid stimulating hormone (TSH). CASEWe report a 3-month-old male, born term via spontaneous vaginal delivery was referred to us at day 13 of life for inappropriately high TSH: 7.69 mIU/L (NV: 0.39–7.0) and high FT4: 57.5 mIU/L (NV: 8.7–16.2). His birth weight was 3.5 kg. Antenatally, his mother has no thyroid disorder. He is the only child of non-consanguineous parents. The cord TSH was 22.01 mIU/L. At day 3 of li

APA, Harvard, Vancouver, ISO, and other styles

14

Tomizawa, Daisuke, Akio Tawa, Tomoyuki Watanabe, et al. "Appropriate Dose Modification in Induction Therapy Is Essential for the Treatment of Infants with Acute Myeloid Leukemia; A Report From the Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG)." Blood 120, no. 21 (2012): 2615. http://dx.doi.org/10.1182/blood.v120.21.2615.2615.

Full text

Abstract:

Abstract Abstract 2615 Background: Infants (age <1 year) with AML are naturally vulnerable to intensive cytotoxic therapy, and we have previously reported unacceptably high early death rate mainly due to pulmonary complications among the first 32 infants (28 eligible) enrolled in the JPLSG AML-05 study, which prompted us to suspension of patient accrual and protocol amendment (Tomizawa D. 52ndASH abstract #2146). Seventeen additional infants were enrolled after the amendment, and here we report the final outcome of total 45 infants with AML treated on AML-05 study. Patients & Methods: J

APA, Harvard, Vancouver, ISO, and other styles

15

Mills, S. J., A. R. Kampf, A. G. Christy, et al. "Bluebellite and mojaveite, two new minerals from the central Mojave Desert, California, USA." Mineralogical Magazine 78, no. 5 (2014): 1325–40. http://dx.doi.org/10.1180/minmag.2014.078.5.15.

Full text

Abstract:

AbstractBluebellite, Cu6[I5+O3(OH)3](OH)7Cl and mojaveite, Cu6[Te6+O4(OH)2](OH)7Cl, are new secondary copper minerals from the Mojave Desert. The type locality for bluebellite is the D shaft, Blue Bell claims, near Baker, San Bernardino County, California, while cotype localities for mojaveite are the E pit at Blue Bell claims and also the Bird Nest drift, Otto Mountain, also near Baker. The two minerals are very similar in their properties. Bluebellite is associated particularly with murdochite, but also with calcite, fluorite, hemimorphite and rarely dioptase in a highly siliceous hornfels.

APA, Harvard, Vancouver, ISO, and other styles

16

Radchikov, V. F., V. P. Tzai, S. N. Razumovskiy, I. F. Gorlov, and M. I. Slozhenkina. "Application of malt sprouts in combine feeds KR-1 when feeding young cattle." Agrarian-And-Food Innovations 14 (June 29, 2021): 68–82. http://dx.doi.org/10.31208/2618-7353-2021-14-68-82.

Full text

Abstract:

Aim. Development of KR-1 concentrate compound feed compositions with the inclusion of malt sprouts, determination of the optimal rates for the introduction of malt sprouts into the compound feed for calves aged 10-75 days. Materials and Methods. In the course of the study, zootechnical, biochemical and mathematical methods of analysis were used. The obtained digital material was processed by the method of variation statistics, taking into account the Student's t-test, using the Microsoft Excel software package. Results. On the basis of the control feedings carried out for the period of the exp

APA, Harvard, Vancouver, ISO, and other styles

17

Patel, Priti, Mayra Telesca, and De-Hui Ku. "The Comparison of Fibrin Monomer (FM) Performance to Other Activation Markers (TAT, PF1.2 and DD)." Blood 118, no. 21 (2011): 5259. http://dx.doi.org/10.1182/blood.v118.21.5259.5259.

Full text

Abstract:

Abstract Abstract 5259 In this study, we attempted to determine the performance of the soluble fibrin monomer complex (SFMC) test in comparison to known activation markers, such as prothrombin fragment 1.2 (PF1.2), thrombin antithrombin complex (TAT) and d-dimer (DD). We have used the STA(R)-Liatest FM and STA(R)-Liatest D-Di kits to measure the SFMC and d-dimer levels. A total of 25 patients were included in this study. The data and demographic information are shown in the table below. ID GENDER AGE FM TAT PF1.2 D-dimer 1 M 66 0.42 2.3 1988 0.05 2 F 31 27.93 >60.0 >12000 2.39 3 F 24 3.4

APA, Harvard, Vancouver, ISO, and other styles

18

Bai, Johnny W., Mandeep Singh, Anthony Short, et al. "Intrathecal Morphine and Pulmonary Complications after Arthroplasty in Patients with Obstructive Sleep Apnea." Anesthesiology 132, no. 4 (2020): 702–12. http://dx.doi.org/10.1097/aln.0000000000003110.

Full text

Abstract:

Abstract Background Intrathecal morphine is commonly and effectively used for analgesia after joint arthroplasty, but has been associated with delayed respiratory depression. Patients with obstructive sleep apnea may be at higher risk of postoperative pulmonary complications. However, data is limited regarding the safety of intrathecal morphine in this population undergoing arthroplasty. Methods This retrospective cohort study aimed to determine the safety of intrathecal morphine in 1,326 patients with documented or suspected obstructive sleep apnea undergoing hip or knee arthroplasty. Chart r

APA, Harvard, Vancouver, ISO, and other styles

19

MacMillan, Margaret L., Bruce R. Blazar, Todd E. Defor, et al. "Alternative Donor Hematopoietic Cell Transplantation for Patients with Fanconi Anemia." Blood 120, no. 21 (2012): 3081. http://dx.doi.org/10.1182/blood.v120.21.3081.3081.

Full text

Abstract:

Abstract Abstract 3081 Hematopoietic cell transplantation (HCT) is the only proven curative therapy for the hematological abnormalities in patients with Fanconi anemia (FA). In the mid-1990s, survival after alternative donor (AD)-HCT was reported to be 18% with excessive rates of regimen-related toxicity, graft failure, graft-versus-host-disease (GVHD) and opportunistic infections (OI). Between 1990 and 2010, 127 FA patients underwent AD-HCT at the University of Minnesota using one of 5 consecutive, prospective phase I-II total body irradiation (TBI) containing clinical trials, representing th

APA, Harvard, Vancouver, ISO, and other styles

20

Tarantino, Michael D., Michael Vredenburg, Wei Tian, Brian Jamieson, and Kashyap B. Patel. "Efficacy Analyses from the Immune Thrombocytopenia (ITP) Clinical Development Program for Avatrombopag: Comparisons with Placebo and Eltrombopag." Blood 136, Supplement 1 (2020): 23–24. http://dx.doi.org/10.1182/blood-2020-142788.

Full text

Abstract:

Background: Management of ITP following failure of 1st line therapy, such as corticosteroids or intravenous immunoglobulin, continues to evolve. The use of thrombopoietin receptor agonists (TPO-RAs) as a subsequent therapeutic approach has become more common, which is supported by the recent American Society of Hematology guidelines (Neunert 2019). The oral TPO-RA eltrombopag (ELT) has an established efficacy profile but also carries an FDA boxed safety warning for hepatotoxicity, necessitating hepatic function monitoring. Additionally, ELT acts as a chelating agent, thus requiring administrat

APA, Harvard, Vancouver, ISO, and other styles

21

Lin, Lin, Haijun Wang, Yongjian Wang, Jian Wang, Yang Liu, and Jiakuo Yu. "Double-Bundle Versus Single-Bundle Anterior Cruciate Ligament Reconstruction in Patients With Significant Passive Anterior Tibial Subluxation." American Journal of Sports Medicine 50, no. 4 (2022): 943–50. http://dx.doi.org/10.1177/03635465211072562.

Full text

Abstract:

Background: Passive anterior tibial subluxation (PATS) is often observed in patients with anterior cruciate ligament tears. Postoperative outcomes of double-bundle (DB) and single-bundle (SB) anterior cruciate ligament reconstruction (ACLR) with significant PATS (>6 mm) are unclear. Hypothesis: DB-ACLR could achieve better stability and clinical outcomes than SB-ACLR in patients with PATS >6 mm. Study Design: Cohort study; Level of evidence, 3. Methods: Retrospective analysis was peformed on 626 consecutive patients who underwent primary anatomic ACLR between October 2016 and November 20

APA, Harvard, Vancouver, ISO, and other styles

22

Rivera Teran, V., D. X. Xibille Friedmann, D. Vega-Morales, et al. "AB1358 BIOLOGIC TREATMENT SUSPENSION AND ASSOCIATED FACTORS IN PATIENTS WITH RHEUMATIC DISEASES DURING THE COVID-19 PANDEMIC: DATA FROM MEXICAN ADVERSE REGISTRY (BIOBADAMEX)." Annals of the Rheumatic Diseases 82, Suppl 1 (2023): 1909.2–1910. http://dx.doi.org/10.1136/annrheumdis-2023-eular.5232.

Full text

Abstract:

BackgroundThe COVID-19 pandemic triggered serious challenges in the treatment of chronic diseases due to the lack of access to medical attention. Patients with rheumatic diseases (RD) must have adequate treatment compliance in order to reach and maintain remission or low activity of their diseases. Treatment suspension because of non-medical reasons might lead to disease activation and organ damage.ObjectivesIdentify the frequency of biologic treatment (bDMARD) suspension in patients with RD during the COVID-19 pandemic and determine the associated factors for suspension.MethodsIn this study w

APA, Harvard, Vancouver, ISO, and other styles

23

Wang, Zifan, Gowtham Asokan, Jukka-Pekka Onnela, et al. "Menarche and Time to Cycle Regularity Among Individuals Born Between 1950 and 2005 in the US." JAMA Network Open 7, no. 5 (2024): e2412854. http://dx.doi.org/10.1001/jamanetworkopen.2024.12854.

Full text

Abstract:

ImportanceEarly menarche is associated with adverse health outcomes. Trends toward earlier menarche have been observed in the US, but data remain limited on differences by sociodemographic factors and body mass index (BMI). Time from menarche to cycle regularity is another understudied early-life characteristic with health implications.ObjectivesTo evaluate the temporal trends and disparities in menarche and time to regularity and explore early-life BMI as a mediator.Design, Setting, and ParticipantsThis ongoing cohort study enrolled participants from an ongoing mobile application–based US coh

APA, Harvard, Vancouver, ISO, and other styles

24

Nguyen, Daniel, Farhad Ravandi, Sa A. Wang, et al. "A Phase II Study of Vibecotamab, a CD3-CD123 Bispecific T-Cell Engaging Antibody, for MDS or CMML after Hypomethylating Failure and in MRD-Positive AML." Blood 142, Supplement 1 (2023): 322. http://dx.doi.org/10.1182/blood-2023-190693.

Full text

Abstract:

Background Leukemic stem cells have high expression of CD123 compared to normal hematopoietic stem cells and is therefore a therapeutic target in multiple leukemias including acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and chronic myelomonocytic leukemia (CMML). Vibecotamab (formally XmAb14045) is a CD3-CD123 bispecific engaging antibody that has shown clinical activity in relapsed/refractory AML, particularly in low-blast disease. We therefore sought to evaluate vibecotamab in other low-blast states, including MDS or CMML after hypomethylating agent failure and MRD-positive

APA, Harvard, Vancouver, ISO, and other styles

25

Mercado, Marta Ruiz, Estrella Carrillo Cruz, Fátima de la Cruz Vicente, et al. "The Role Of 18F-FDG PET/CT For Staging and Response Assessment To Chemotherapy In Marginal Zone Lymphoma." Blood 122, no. 21 (2013): 4328. http://dx.doi.org/10.1182/blood.v122.21.4328.4328.

Full text

Abstract:

Abstract Introduction Marginal Zone Lymphoma (MZL) is an indolent lymphoma in which the use of PET/CT is poorly explored and also controversial due to the heterogeneous 18F- FDG avidity described in these types of lymphoma. Our aim in the present study is to evaluate the role of 18F-FDG-PET/ CT (PET/CT) in comparison to CT with intravenous contrast enhancement at initial staging and response assessment to chemotherapy in these patients. Methods and Materials A retrospective single-center study that included 34 patients, diagnosed of MZL between 1998 and 2012, with at least one PET/CT available

APA, Harvard, Vancouver, ISO, and other styles

26

Krop, Ian, Dejan Juric, Toshio Shimizu, et al. "Abstract GS1-05: Datopotamab deruxtecan in advanced/metastatic HER2- breast cancer: Results from the phase 1 TROPION-PanTumor01 study." Cancer Research 82, no. 4_Supplement (2022): GS1–05—GS1–05. http://dx.doi.org/10.1158/1538-7445.sabcs21-gs1-05.

Full text

Abstract:

Abstract Background: Datopotamab deruxtecan (Dato-DXd) is an antibody-drug conjugate consisting of a humanized anti-TROP2 IgG1 monoclonal antibody conjugated to a potent topoisomerase I inhibitor payload via a stable tetrapeptide-based cleavable linker. Preliminary results from the phase 1 TROPION-PanTumor01 study demonstrate that Dato-DXd has encouraging antitumor activity and a manageable safety profile in patients with non-small cell lung cancer (NSCLC) (Meric-Bernstam, ASCO 2021) and those with triple-negative breast cancer (TNBC) (Bardia, ESMO BC 2021). Updated results from the TNBC cohor

APA, Harvard, Vancouver, ISO, and other styles

27

Chandesris, Marie-Olivia, Gandhi Damaj, Danielle Canioni, et al. "Treatment of Advanced Systemic Mastocytosis with PKC412: The French Compassionate Use Programme Experience and Historical Comparison." Blood 124, no. 21 (2014): 3193. http://dx.doi.org/10.1182/blood.v124.21.3193.3193.

Full text

Abstract:

Abstract Background Advanced Systemic Mastocytosis (adSM) still have very poor prognosis. No standard of care is yet available. Midostaurin (PKC412) is a powerful TKI inhibit of VEGFR, FLT3 and most importantly the mutated CKITD816V and D816Y. Preliminarily results from an international phase II trial (Gotlib et al., Blood 2012) reported interesting results in this subgroup of patients. We report herein on the French experience of the compassionate use of PKC412 for the treatment of adSM and compare their outcome to matched adSM historical control patients (pts) who did not receive PKC412 (con

APA, Harvard, Vancouver, ISO, and other styles

28

Ergas, Isaac, Janise Roh, Lawrence Kushi, et al. "Abstract PO1-11-05: Diet quality and cardiovascular disease risk among breast cancer survivors in the Pathways Study." Cancer Research 84, no. 9_Supplement (2024): PO1–11–05—PO1–11–05. http://dx.doi.org/10.1158/1538-7445.sabcs23-po1-11-05.

Full text

Abstract:

Abstract Background: While studies have shown that breast cancer survivors with healthier diets have a lower risk of non-breast cancer-specific and all-cause mortality after a breast cancer diagnosis, the relationship between diet quality and cardiovascular disease (CVD) among breast cancer survivors is not well characterized. We examined the association between diet quality at the time of breast cancer diagnosis and CVD-related outcomes in the Pathways Study, a prospective cohort of 3,415 women diagnosed with invasive breast cancer. Methods: This analysis included four diet quality indices (D

APA, Harvard, Vancouver, ISO, and other styles

29

Forconi, Francesco, Emanuele Cencini, Francesco Zaja, et al. "Analysis of Parameters Predicting Treatment Efficacy and Outcome In Patients with Hairy Cell Leukemia (HCL) Receiving Subcutaneous Cladribine In the ICGHCL2004 Protocol (by the Italian Cooperative Group on HCL)." Blood 116, no. 21 (2010): 1369. http://dx.doi.org/10.1182/blood.v116.21.1369.1369.

Full text

Abstract:

Abstract Abstract 1369 Introduction: Single-agent cladribine (2CdA) given intravenously or subcutaneously (sc) is highly effective in Hairy cell leukemia (HCL). However, HCL patients are projected to progress in their life-span or, in a minority, are refractory and may benefit from other treatment strategies. Parameters predicting efficacy of (sc)2CdA in HCL are scarcely known. Aims: In a national multicentre clinical trial (EudraCT code: ICGHCL2004) we prospectively sought parameters able to predict efficacy of sc2CdA in classic HCL requiring first treatment (1987 Consensus Criteria). Methods

APA, Harvard, Vancouver, ISO, and other styles

30

Rahman, P., C. T. Ritchlin, P. Helliwell, et al. "FRI0359 INTEGRATED SAFETY RESULTS OF TWO PHASE-3 TRIALS OF GUSELKUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS THROUGH THE PLACEBO-CONTROLLED PERIODS." Annals of the Rheumatic Diseases 79, Suppl 1 (2020): 776–77. http://dx.doi.org/10.1136/annrheumdis-2020-eular.387.

Full text

Abstract:

Background:DISCOVER 1 & 2 are phase 3 psoriatic arthritis (PsA) trials investigating guselkumab (GUS), an IL-23 inhibitor that specifically binds the IL-23p19 subunit. In both studies, GUS showed significant improvement vs placebo (PBO) through week (W) 24 in the PBO-controlled period.1,2Objectives:To present integrated safety results of DISC 1 & 2 through the PBO-controlled periods.Methods:Adult patients (pts) with active PsA despite standard therapy were enrolled. All pts were biologic-naïve, except ~30% in DISC 1 with previous exposure to 1-2 TNF inhibitors. Pts were randomized to S

APA, Harvard, Vancouver, ISO, and other styles

31

Deodhar, A., D. Van der Heijde, L. S. Gensler, et al. "POS0939 BIMEKIZUMAB IN PATIENTS WITH ACTIVE NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: 24-WEEK EFFICACY & SAFETY FROM BE MOBILE 1, A PHASE 3, MULTICENTRE, RANDOMISED, PLACEBO‑CONTROLLED STUDY." Annals of the Rheumatic Diseases 81, Suppl 1 (2022): 772–73. http://dx.doi.org/10.1136/annrheumdis-2022-eular.2416.

Full text

Abstract:

BackgroundBimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits IL-17F in addition to IL-17A. BKZ has shown rapid and sustained efficacy and was well tolerated up to 156 weeks (wks) in a phase 2b study in patients (pts) with active ankylosing spondylitis.1,2ObjectivesTo assess efficacy and safety of BKZ vs placebo (PBO) in pts with active non-radiographic axial spondyloarthritis (nr-axSpA) up to Wk 24 in the ongoing pivotal phase 3 study, BE MOBILE 1.MethodsBE MOBILE 1 (NCT03928704) comprises a 16-wk double-blind, PBO-controlled period and 36-wk maintenance period. Pts were

APA, Harvard, Vancouver, ISO, and other styles

32

Marrero-Gonzalez, Alejandro R., Anna Crawford, Fitzgerald Draper, Andrea Incudine, Stacy Tessler Lindau, and Evan M. Graboyes. "Abstract 1016: Food insecurity among patients with cancer in the US." Cancer Research 84, no. 6_Supplement (2024): 1016. http://dx.doi.org/10.1158/1538-7445.am2024-1016.

Full text

Abstract:

Abstract Introduction: Food insecurity (FI) is common among cancer patients and can lead to decreased treatment adherence, worse quality of life, and increased recurrence and mortality. Although some studies suggest that patients with cancer are particularly susceptible to FI, these studies have been limited by their small sample size, narrow sampling of cancer types and stages, and limited geographic scope. To address this gap, this study leverages data from a supportive care organization to characterize FI prevalence and associated risk factors in a nationwide sample of patients with diverse

APA, Harvard, Vancouver, ISO, and other styles

33

Gugliotta, Luigi, Carlos Besses, Martin Griesshammer, et al. "Combination of Cytoreductive Therapies in Patients with Essential Thrombocythemia: A Preliminary Report From the E.X.E.L.S. Study." Blood 120, no. 21 (2012): 2842. http://dx.doi.org/10.1182/blood.v120.21.2842.2842.

Full text

Abstract:

Abstract Abstract 2842 Background: As some patients (pts) with essential thrombocythemia (ET) may discontinue their cytoreductive treatment because of drug intolerance/inefficacy, combinations of drugs with different activity/tolerability patterns are being utilized in clinical practice. Objectives: To evaluate the clinical relevance and patterns of cytoreductive combination treatment in ET in Evaluation of Xagrid™ Efficacy and Long-term Safety (EXELS), an observational study in 3643 European pts with high-risk ET. Patients and Methods: Data on pts receiving cytoreductive treatments in combina

APA, Harvard, Vancouver, ISO, and other styles

34

Xavier, Juliana M., Ricon Lauremília, Vieira Karla, et al. "Arhgap21+/- Mice Show Impaired Adhesion, Migration, Homing and Short Term Reconstitution of Hematopoietic Progenitor Cells." Blood 124, no. 21 (2014): 4333. http://dx.doi.org/10.1182/blood.v124.21.4333.4333.

Full text

Abstract:

Abstract The main signaling pathway involved in migration, adhesion and homing of hematopoietic progenitor cells (HPC) is the CXCL-12, chemokine produced by bone marrow (BM) stromal cells that bind to its main receptor CXCR-4, expressed by HPC. ARHGAP21 is a RhoGAP member, negative regulators of RhoGTPAses. It was described that ARHGAP21 is involved in cellular migration and adhesion but its role in hematopoiesis is unknown. Researching Arhgap21 role in hematopoiesis, Arhgap21+/- mice were generated using Embryonic Stem cell obtained from GeneTrap consortium. Hematologic parameters were invest

APA, Harvard, Vancouver, ISO, and other styles

35

Dennis, Michael, Nigel H. Russell, Nicki Panoskaltsis, et al. "A Randomised Assessment of Vosaroxin Monotherapy and Vosaroxin Combined with Low Dose Ara-C Versus Low Dose Ara-C in Older Patients with Acute Myeloid Leukaemia." Blood 124, no. 21 (2014): 3747. http://dx.doi.org/10.1182/blood.v124.21.3747.3747.

Full text

Abstract:

Abstract The older patient with AML represents an important subgroup who are often not considered fit for traditional “3+7” type chemotherapy. Although demethylation agents and low dose Ara-c (LDAC) are superior to best supportive care, other options have so far failed to improve survival which is typically 3-4 months. Much of the problem could be attributed to chemoresistance of the leukaemic clone. Vosaroxin is a first in class anti-cancer quinolone which by intercalating into DNA has topoisomerase II inhibitory properties and can by-pass resistance mediated by P-glycoprotein or P53. This re

APA, Harvard, Vancouver, ISO, and other styles

36

Fazaa, A., A. Mahbouli, S. Miladi, et al. "AB1522 THE ASSESSMENT OF KNOWLEDGE OF NURSES BEFORE AND AFTER TRAINING ABOUT SPONDYLOARTHRITIS AND RHEUMATOID ARTHRITIS." Annals of the Rheumatic Diseases 81, Suppl 1 (2022): 1863. http://dx.doi.org/10.1136/annrheumdis-2022-eular.5283.

Full text

Abstract:

BackgroundNurses’ education programs play an important role in the management of chronic diseases in rheumatology clinics. They can assume their own patient case-loads and provide an educative role to promote health.ObjectivesIn order to foster educational programs, the present study aimed to assess the level of knowledge of nurses before and after targeted training sessions.MethodsThe nurses of the rheumatology department of Mongi Slim Hospital have been included initially during the month of September 2021, then later, after having followed a training during the month of January 2022.Data we

APA, Harvard, Vancouver, ISO, and other styles

37

Vachhani, Pankit, Jennifer Repp, JE Hamer-Maansson, Evan M. Braunstein, Valkal Bhatt, and Haifa Kathrin Al-Ali. "Clinical Outcomes in Patients with Myelofibrosis Treated with Ruxolitinib and Anemia-Supporting Medications." Blood 144, Supplement 1 (2024): 4546. https://doi.org/10.1182/blood-2024-203924.

Full text

Abstract:

Introduction: Patients with myelofibrosis (MF) often present with anemia, and dose-dependent anemia is a known consequence of treatment with the Janus kinase (JAK)1/JAK2 inhibitor ruxolitinib. Current guidelines recommend erythropoiesis-stimulating agents (ESAs) and danazol as options to manage anemia in this population. However, data are lacking regarding the clinical outcomes of patients with MF treated with ruxolitinib and these agents. This post hoc analysis of the phase 3 JUMP trial, the largest ruxolitinib trial to date, evaluated treatment patterns and clinical outcomes of ruxolitinib-t

APA, Harvard, Vancouver, ISO, and other styles

38

Combe, B., Y. Tanaka, P. Emery, et al. "POS0679 CLINICAL OUTCOMES UP TO WEEK (W) 48 IN THE ONGOING FILGOTINIB (FIL) LONG-TERM EXTENSION (LTE) TRIAL OF RHEUMATOID ARTHRITIS (RA) PATIENTS (pts) WITH INADEQUATE RESPONSE (IR) TO METHOTREXATE (MTX) INITIALLY TREATED WITH FIL OR ADALIMUMAB (ADA) DURING THE PHASE 3 PARENT STUDY (PS)." Annals of the Rheumatic Diseases 81, Suppl 1 (2022): 615–16. http://dx.doi.org/10.1136/annrheumdis-2022-eular.1641.

Full text

Abstract:

BackgroundThe preferential Janus kinase-1 inhibitor FIL is approved for treatment of moderate to severe active RA in Europe and Japan.ObjectivesEfficacy and safety of FIL were assessed in pts with IR to MTX who completed a Phase 3 trial (NCT02889796)1 and enrolled in an LTE (NCT03025308).MethodsPts completing the PS1 on study drug were eligible to enter the LTE (data cutoff: June 1, 2020). Median exposure: 2.2 years (y). Efficacy data to W48 are reported for 4 treatment groups (all with background MTX): pts receiving FIL 200 mg (FIL200) or FIL 100 mg (FIL100) in the PS and continuing their dos

APA, Harvard, Vancouver, ISO, and other styles

39

Sasaki, Koji, Ildefonso Ismael Rodriguez-Rivera, Hagop M. Kantarjian, et al. "Correlation of Lymphocyte Count with Treatment Response to Tyrosine Kinase Inhibitors in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase." Blood 124, no. 21 (2014): 4538. http://dx.doi.org/10.1182/blood.v124.21.4538.4538.

Full text

Abstract:

Abstract Background: Total lymphocyte count (TLC) has been shown to correlate with outcomes in patients (pts) with acute leukemia. The clinical correlation to TLC in pts with chronic myeloid leukemia in chronic phase (CML-CP) who were treated with a tyrosine-kinase inhibitor (TKI) is unclear. Methods: Lymphocyte data in pts with newly diagnosed CML-CP who were enrolled in consecutive or parallel clinical trials with front-line imatinib (IM), nilotinib (Nilo), or dasatinib (Dasa) were collected at the time of diagnosis, and 3 and 6 months (M) after the start of TKI. Relative lymphocytrosis (RLC

APA, Harvard, Vancouver, ISO, and other styles

40

Moreau, Philippe, A. Keith Stewart, Antonio Lazzaro, et al. "Efficacy and Safety of Once-Weekly vs Twice-Weekly Carfilzomib Plus Dexamethasone: Subgroup Analysis of the Phase 3 A.R.R.O.W. Study (NCT02412878) By Prior Lines." Blood 132, Supplement 1 (2018): 3244. http://dx.doi.org/10.1182/blood-2018-99-114863.

Full text

Abstract:

Abstract Introduction: The phase 3 A.R.R.O.W. study (NCT02412878) has shown a favorable benefit-risk profile of once-weekly carfilzomib (K) at 70 mg/m2 over twice-weekly K at 27mg/m2 plus dexamethasone (d) for the treatment of patients (pts) with relapsed and refractory multiple myeloma (RRMM) (Moreau. Lancet Oncol. 2018;19:953-964). Once-weekly significantly improved progression-free survival (PFS) compared with twice-weekly (median 11.2 vs 7.6 months [mos]; hazard ratio [HR]: 0.69; 95% confidence interval [CI]: 0.54, 0.88; P=0.0014). Herein, we present a subgroup analysis of once-weekly vs t

APA, Harvard, Vancouver, ISO, and other styles

41

Sara, Mohamed Fouad, Gaber Marei Ahmed, and Abd el aziz Ahmed. "Timing of repeated head computerised tomography and its impact on the management of patients with moderate and severe traumatic brain injury (TBIS)." Biolife 4, no. 3 (2022): 547–69. https://doi.org/10.5281/zenodo.7334054.

Full text

Abstract:

<strong>ABSTRACT</strong> The purpose of this prospective study over 100 patients who were admitted to surgical emergency unit was to define the indications, the timing and the frequency of repeated head computerized tomography (CT) scan in patients with moderate and severe traumatic brain injuries (TBIs) and to verify its impact on the management of those patients. we found that Performing an initial early CT brain within 2 hours interval from onset of trauma had a significance in comparison to 4 hours and 6 hours interval, none of the follow up CTs done upon improvement of GCS show any chang

APA, Harvard, Vancouver, ISO, and other styles

42

Clauss, Delphine, Vincent Martin, Jakub Drnec, Marta Mirolo, Laetitia Dubau, and Frederic Maillard. "Deciphering the Roles of Chemistry and Structure in Iridium Oxide Oxygen Evolution Catalysts through the Study of Annealed Iridium Oxide Nanoparticles." ECS Meeting Abstracts MA2023-02, no. 42 (2023): 2080. http://dx.doi.org/10.1149/ma2023-02422080mtgabs.

Full text

Abstract:

The development of proton exchange membrane (PEM) water electrolysis, which enables the production of de-carbonized hydrogen, is hindered by the low efficiency of the oxygen evolution reaction (OER). This is especially true in acidic environment where only noble metals (mainly Ru and Ir) can be used as electrocatalysts. Iridium oxide nanocatalysts (IrOx) are promising due to their high OER activity and good resistance to acidic and oxidative conditions. However, finding a compromise between their electrocatalytic activity and stability remains challenging. Moreover, it is not yet clear which p

APA, Harvard, Vancouver, ISO, and other styles

43

Haferlach, Torsten, Ulrike Bacher, Tamara Alpermann, et al. "Further Insights Into The Molecular Landscape Of De Novo Acute Myeloid Leukemia (AML) Investigating 1,291 Patients." Blood 122, no. 21 (2013): 607. http://dx.doi.org/10.1182/blood.v122.21.607.607.

Full text

Abstract:

Abstract Background The Cancer Genome Atlas Research Network (TCGA) published a hallmark sequencing study on molecular mutations in 200 fully characterized adult de novo AML (NEJM 2013). According to their data AML harbor in average 13 mutations in the coding region of the genome of which 5 are in genes known to be recurrently mutated in AML. Further, detailed data on co-occurrence and mutual exclusiveness of molecular mutations was presented. However, given the heterogeneity of AML a cohort of 200 AML might not be fully representative. Aims 1. Compare the published mutation frequency to our c

APA, Harvard, Vancouver, ISO, and other styles

44

Loo, Sun, Nicola Potter, Adam Ivey, et al. "Pre-Transplant Measurable Residual Disease (MRD) Detection of KMT2A-rearranged Acute Myeloid Leukemia Is Strongly Associated with Inferior Post-Transplant Outcome." Blood 142, Supplement 1 (2023): 1577. http://dx.doi.org/10.1182/blood-2023-185541.

Full text

Abstract:

Introduction KMT2A-rearranged ( KMT2Ar ) acute myeloid leukemia (AML) is associated with inferior survival and allogeneic hematopoietic cell transplant (HCT) in first remission (CR1) is an important post-remission objective (Issa et al, Blood Cancer Journal 2021). Despite HCT, however, the relapse risk is ~50% (Menghrajani et al, Blood Adv. 2022). Several small cohort studies have described the prognostic utility of pre-HCT MRD assessment using real-time reverse transcription quantitative polymerase chain reaction (RT-qPCR), but currently, this is not standard practice (Scholl et al, Haematolo

APA, Harvard, Vancouver, ISO, and other styles

45

Castillo, Jorge J., Joshua Gustine, Maria Demos, et al. "Clinical and Genomic Factors Are Predictive of Response and Prognostic of Progression-Free Survival in Patients with Waldenström Macroglobulinemia Treated with Ibrutinib." Blood 134, Supplement_1 (2019): 2823. http://dx.doi.org/10.1182/blood-2019-125069.

Full text

Abstract:

Introduction: The Bruton tyrosine kinase inhibitor ibrutinib is the only FDA approved therapy for the treatment of symptomatic Waldenstrom macroglobulinemia (WM), and has been associated with high response rates and durable progression-free survival (PFS). Factors associated with depth of response and PFS duration are not well established. We performed a retrospective study aimed at identifying predictive and prognostic factors in WM patients treated with ibrutinib. Methods: We included consecutive patients with a diagnosis of WM treated with ibrutinib monotherapy evaluated at the Dana-Farber

APA, Harvard, Vancouver, ISO, and other styles

46

Fahey, Margaret C., Marion E. Hare, Gerald W. Talcott, et al. "Characteristics Associated With Participation in a Behavioral Weight Loss Randomized Control Trial in the U.S. Military." Military Medicine 184, no. 3-4 (2018): e120-e126. http://dx.doi.org/10.1093/milmed/usy199.

Full text

Abstract:

Abstract Introduction Effective recruitment and subsequent enrollment of diverse populations is often a challenge in randomized controlled trials, especially those focused on weight loss. In the civilian literature, individuals identified as racial and ethnic minorities, men, and younger and older adults are poorly represented in weight loss interventions. There are limited weight loss trials within military populations, and to our knowledge, none reported participant characteristics associated with enrollment. There may be unique motives and barriers for active duty personnel for enrollment i

APA, Harvard, Vancouver, ISO, and other styles

47

Wang, Yucai, Melissa C. Larson, Alessia Castellino, et al. "Event-Free Survival at 24 Months (EFS24) Becomes an Important Clinical Endpoint in Newly Diagnosed Mantle Cell Lymphoma in the New Era." Blood 138, Supplement 1 (2021): 2429. http://dx.doi.org/10.1182/blood-2021-147538.

Full text

Abstract:

Abstract Background: Event-free survival at 24 months (EFS24) is an important clinical endpoint in newly diagnosed diffuse large B-cell lymphoma and follicular lymphoma, and patients who achieve EFS24 with frontline immunochemotherapy have minimal loss of lifetime compared to age- and sex-matched general population. However, the prognostic role of EFS24 in mantle cell lymphoma (MCL) has not been well studied, possibly due to the perception of continued relapse pattern and poor survival outcome of MCL historically. A recent study from our group demonstrated evolving frontline therapy pattern fr

APA, Harvard, Vancouver, ISO, and other styles

48

Wesseling, Jelle. "Abstract F1-2: Clonal evolution of DCIS to invasion." Cancer Research 83, no. 5_Supplement (2023): F1–2—F1–2. http://dx.doi.org/10.1158/1538-7445.sabcs22-f1-2.

Full text

Abstract:

Abstract Clonal evolution of DCIS to invasion Ductal carcinoma in situ (DCIS) is the most common form of preinvasive breast cancer and, despite treatment, a small fraction (5-10%) of DCIS patients develop subsequent invasive breast cancer (IBC). If not treated, at least 3 out of 4 women with DCIS will not develop IBC1-3. This implies many women with non-progressive, low-risk DCIS are likely to carry the burden of overtreatment. To solve this DCIS dilemma, two fundamental questions need to be answered. The first question is, how the subsequent IBC is related to the initial DCIS lesion. The seco

APA, Harvard, Vancouver, ISO, and other styles

49

Крюков, В. А. "Выявить, донести, реализовать. Институту исследования Сибири – 100 лет". Журнал «ЭКО» 49, № 2 (2019): 4. http://dx.doi.org/10.30680/eco0131-7652-2019-2-4-7.

Full text

Abstract:

<p class="_7Osnovnoi-text" lang="ru-RU"><span class="CharOverride-2" lang="ar-SA">Экономическая наука, как и любая другая область познания окружающего мира, развивается от постижения отдельных фактов и явлений к формированию более общей и связной картины изучаемой действительности, а затем если и рассматривает частности, то уже на новом уровне осмысления. Это касается как науки в целом, так и отдельных ее предметов и областей, что прекрасно иллюстрирует этот номер журнала.</span></p><p class="_7Osnovnoi-text" lang="ru-RU"><span class="CharOverride-2" lang="ar-S

APA, Harvard, Vancouver, ISO, and other styles

50

Divya, Teja D., and Vardhani Viveka. "Influence of Gene Vac B vaccine on the abdominal muscle MDA in the immunostimulated male swiss albino mice." Biolife 4, no. 1 (2022): 68–73. https://doi.org/10.5281/zenodo.7309976.

Full text

Abstract:

<strong>ABSTRACT</strong> Malondialdehyde (MDA) is a naturally occurring product of lipid peroxidation, initiated by free radicals (causing oxidative stress by reactive oxygen species - ROS). MDA is highly mutagenic and carcinogenic and plays a significant role in disease pathogenesis by disturbing the immune response and forms immune complexes that may be deposited in various tissues. This study is centralized on the immunostimulatory effect of Immunex DS (IDS) on the MDA level in abdominal muscle tissue of mice against Gene Vac B vaccine. Eight groups of male swiss albino mice (10 in each) w

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!